Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

2013: The year’s biggest Drug Development stories

Alkermes reported positive results from a Phase I study of schizophrenia drug ALKS 3831 while Takeda secured European approval for three new type 2 diabetes therapies Vipidia, Vipdomet and Incresync. Drugdevelopment-technology.com wraps-up the key headlines from 2013.

Go Top